Myeloperoxidase Inhibition Ameliorates Plaque Psoriasis in Mice.

Autor:	Neu SD; Versiti Blood Research Institute, Milwaukee, WI 53201, USA.; Department of Microbiology & Immunology, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Strzepa A; Versiti Blood Research Institute, Milwaukee, WI 53201, USA.; Department of Medical Biology, Jagiellonian University Medical College, 31-034 Krakow, Poland., Martin D; Department of Surgery, Division of Pediatric Surgery, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Sorci-Thomas MG; Department of Medicine, Division of Endocrinology & Molecular Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Pritchard KA Jr; Department of Surgery, Division of Pediatric Surgery, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Dittel BN; Versiti Blood Research Institute, Milwaukee, WI 53201, USA.
Jazyk:	angličtina
Zdroj:	Antioxidants (Basel, Switzerland) [Antioxidants (Basel)] 2021 Aug 25; Vol. 10 (9). Date of Electronic Publication: 2021 Aug 25.
DOI:	10.3390/antiox10091338
Abstrakt:	Plaque psoriasis is a common inflammatory condition of the skin characterized by red, flaking lesions. Current therapies for plaque psoriasis target many facets of the autoimmune response, but there is an incomplete understanding of how oxidative damage produced by enzymes such as myeloperoxidase contributes to skin pathology. In this study, we used the Aldara (Imiquimod) cream model of plaque psoriasis in mice to assess myeloperoxidase inhibition for treating psoriatic skin lesions. To assess skin inflammation severity, an innovative mouse psoriasis scoring system was developed. We found that myeloperoxidase inhibition ameliorated psoriasis severity when administered either systemically or topically. The findings of this study support the role of oxidative damage in plaque psoriasis pathology and present potential new therapeutic avenues for further exploration.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu